Infections are the second leading cause of death in cancer patients, after the cancer itself; Zisis Kozlakidis and Shalini Jayasekar Zurn discuss the challenges surrounding the interplay between cancer and antimicrobial resistance (AMR).
A scarcity of suitable therapies and geographic disparities in access to care are impacting survival rates for children with cancer; Lorna Rothery spoke to the European branch of Childhood Cancer International, a pan-European organisation committed to improving outcomes for children and adolescents affected by cancer.
Decades after the ban on asbestos, we still struggle with the impact of mesothelioma – is it possible to eliminate this devastating cancer? We put the question to UK charity Asthma + Lung UK.
A minimally invasive treatment for prostate cancer, using a combination of MRI and transurethral ultrasound, has shown effectiveness in a recent study.
Dr Alice Di Pasquale, Scientific Research Officer at Breast Cancer UK, explains why more must be done to increase awareness of Endocrine Disrupting Chemicals and breast cancer risk.
Researchers have identified 140 genes that could change how non-small cell lung cancer (NSCLC) patients are treated with immunotherapy and low-dose radiation.
Paul Landau, CEO of Careology, a digital cancer care platform used by the NHS and private health sector, posits the need for smart investment into digital tools to support cancer care and maximise the efficiency of resources.
The past ten years have seen significant progress in cancer care, detecting cancers earlier and managing them more successfully and less invasively on a global scale.
Is there a way to mend a broken heart? Biomedical engineers have found a potential way to mend a broken heart using a genetic mutation commonly associated with skin cancers.
Secarna Pharmaceuticals, the next-generation antisense drug discovery and development company, is developing novel approaches to successfully target Neuropilin 1 (NRP1), a promising target for the treatment of cancer.
